Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.71)
# 173
Out of 5,032 analysts
23
Total ratings
78.95%
Success rate
21.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Initiates: Neutral | $21 | $20.99 | +0.05% | 1 | Aug 19, 2025 | |
| JANX Janux Therapeutics | Initiates: Overweight | $42 | $26.76 | +56.95% | 1 | Aug 19, 2025 | |
| RVMD Revolution Medicines | Initiates: Overweight | $75 | $54.10 | +38.63% | 1 | Aug 19, 2025 | |
| URGN UroGen Pharma | Initiates: Overweight | $36 | $16.94 | +112.51% | 4 | Aug 19, 2025 | |
| CGON CG Oncology | Initiates: Overweight | $55 | $41.46 | +32.66% | 1 | Aug 19, 2025 | |
| TNGX Tango Therapeutics | Initiates: Overweight | $11 | $9.03 | +21.82% | 1 | Aug 19, 2025 | |
| NUVL Nuvalent | Initiates: Overweight | $112 | $92.52 | +21.05% | 3 | Aug 19, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $36 | $18.25 | +97.26% | 1 | Aug 19, 2025 | |
| IPSC Century Therapeutics | Reiterates: Buy | n/a | $0.54 | - | 3 | Mar 28, 2025 | |
| GNLX Genelux | Initiates: Buy | $8 | $5.72 | +39.86% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.65 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $86.95 | - | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $31.96 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.18 | - | 1 | Oct 31, 2022 |
Summit Therapeutics
Aug 19, 2025
Initiates: Neutral
Price Target: $21
Current: $20.99
Upside: +0.05%
Janux Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $42
Current: $26.76
Upside: +56.95%
Revolution Medicines
Aug 19, 2025
Initiates: Overweight
Price Target: $75
Current: $54.10
Upside: +38.63%
UroGen Pharma
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $16.94
Upside: +112.51%
CG Oncology
Aug 19, 2025
Initiates: Overweight
Price Target: $55
Current: $41.46
Upside: +32.66%
Tango Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $11
Current: $9.03
Upside: +21.82%
Nuvalent
Aug 19, 2025
Initiates: Overweight
Price Target: $112
Current: $92.52
Upside: +21.05%
Bicara Therapeutics
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $18.25
Upside: +97.26%
Century Therapeutics
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.54
Upside: -
Genelux
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $5.72
Upside: +39.86%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.65
Upside: -
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $86.95
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $31.96
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.18
Upside: -